13F Holdings
中文EN

ETON Eton Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1710340 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY100.6%
TTM net income YoY846.2%
TTM EPS YoY703.3%
Revenue 3-yr CAGR62.6%
Net income 3-yr CAGR181.6%

Margins

Gross margin69.2%
Operating margin28.8%
Net margin35.3%
FCF margin27.1%
EBITDA margin31.4%

Returns

ROE90.6%
ROA38.1%
ROIC (approx.)115.0%
Asset turnover1.08x

Leverage & solvency

Liabilities / assets44.7%
Debt / equity0.27x
Current ratio1.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio8.8%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$79.95M$39.01M$31.64M$21.25M$21.83M
Cost of revenue$37.21M$15.60M$10.58M$6.93M$2.83M
Gross profit$42.74M$23.41M$21.06M$14.32M$19.00M
R&D expense$7.76M$3.25M$3.32M$4.00M$6.24M
SG&A expense$35.82M$22.75M$18.93M$18.58M$14.27M
Operating income-$844,000-$2.60M-$1.19M-$8.26M-$1.50M
Interest expense$4.78M$2.00M$1.06M$955,000$1.04M
Pretax income-$4.56M-$3.81M-$689,000-$9.02M-$1.96M
Income tax$43,000$15,000$247,000$0$0
Net income-$4.60M-$3.82M-$936,000-$9.02M-$1.96M
EBITDA$3.20M-$1.45M-$291,000-$6.49M-$1.03M
EPS (basic)-0.17-0.15-0.04-0.36-0.08
EPS (diluted)————-0.08
Weighted avg. shares (diluted)————25.21M
Balance sheet
Cash & equivalents$25.94M$14.94M$21.39M$16.30M$14.41M
Receivables$11.76M$5.36M$3.41M$1.85M$5.47M
Inventory$15.42M$15.23M$911,000$557,000$550,000
Current assets$60.58M$41.02M$26.84M$20.00M$23.60M
PP&E, net$326,000$34,000$58,000$72,000$115,000
Intangibles$30.88M$34.88M$4.74M$4.75M$3.62M
Total assets$92.11M$76.12M$31.74M$25.03M$27.46M
Current liabilities$38.49M$19.95M$16.24M$6.46M$4.56M
Short-term debt$8.79M$0$5.38M$1.03M$1.42M
Long-term debt$21.77M$29.81M$0$5.38M$5.26M
Total debt$30.56M$29.81M$5.38M$6.42M$6.68M
Total liabilities$65.96M$51.70M$16.26M$11.95M$9.84M
Shareholders' equity$26.15M$24.43M$15.48M$13.08M$17.63M
Net debt$4.62M$14.88M-$16.01M-$9.89M-$7.73M
Shares outstanding27.05M26.71M25.69M25.35M24.63M
Cash flow statement
Operating cash flow$10.52M$969,000$6.82M$4.82M-$4.72M
Capital expenditure$333,000$26,000$0$38,000$9,000
Free cash flow$10.19M$943,000$6.82M$4.78M-$4.73M
Investing cash flow-$333,000-$40.01M-$775,000-$2.79M-$2.56M
Financing cash flow$815,000$32.59M-$957,000-$134,000$391,000
Depreciation & amortization$4.04M$1.15M$901,000$1.77M$462,000
Stock-based compensation$5.51M$3.17M$3.14M$4.22M$3.38M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.